Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis
Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis
复制标题
DOI：
10.1007/s00432-003-0499-6
复制
发表时间：
2003-12-01
影响因子：
3.6
通讯作者：
Tatematsu, M
中科院分区：
文献类型：
--
作者：
Mizoshita, T;Tsukamoto, T;Tatematsu, M
目的。迄今为止，表型和Cdx2表达在胃癌中的临床病理意义尚不清楚。因此，在本研究中，我们研究了晚期病例的预后、表型和Cdx2表达之间的关系。方法。我们对177例晚期胃癌进行组织学和表型评估。免疫组织化学检测Cdx2的表达。结果。病变表型分为胃型（G型）32例，胃肠混合型（GI型）36例，肠型（I型）53例，空型（N型）56例，与组织学分型无关。Cdx2核染色与肠道表型表达密切相关，与组织学分型无关。Cdx2表达与表型的Kaplan-Meier分析结果显示，Cdx2阳性组预后明显优于阴性组（P=0.0013）， GI型患者生存率明显优于N型患者（P=0.0052）。结论。我们的结果表明Cdx2是一个有用的预后标志物。此外，伴有肠和胃两种表型表达的晚期胃癌预后相对较好。胃和肠上皮细胞标志物（包括Cdx2）的联合评估在临床上可用于预测晚期胃肿瘤患者的预后。
Purpose. The clinicopathologic significance of the phenotype and Cdx2 expression has hitherto remained unclear in gastric cancers. In the present study, we therefore examined the correlation between prognosis, phenotype, and Cdx2 expression in advanced cases. Methods. We evaluated 177 advanced gastric carcinomas histologically and phenotypically. The expression of Cdx2 was also assessed by immunohistochemistry. Results. The lesions were phenotypically divided into 32 gastric (G type), 36 gastric and intestinal mixed (GI type), 53 intestinal (I type), and 56 null (N type) types, independent of the histological classification. Cdx2 nuclear staining demonstrated a close relation to intestinal phenotypic expression, not with the histological classification. Kaplan-Meier analysis of Cdx2 expression and the phenotype showed that the Cdx2 positive groups had a significantly better outcome than the negative ones (P=0.0013), and the patients with GI type cancers had significant better survival than those with N type (P=0.0052). Conclusions. Our results suggest that Cdx2 is a useful prognostic marker. In addition, advanced gastric cancers with both intestinal and gastric phenotypic expression have a relatively good prognosis. Combined evaluation of gastric and intestinal epithelial cell markers, including Cdx2, is clinically useful to predict outcome in patients with advanced neoplasm of the stomach.